Children's Hospital LA halts use of Sarepta's gene therapy for all patients
Elevidys was granted full FDA approval last year for children with Duchenne Muscular Dystrophy who can still walk, and received conditional approval for non-ambulatory patients. However, Sarepta suspended use in non-ambulatory cases in June, after two teenagers died of liver failure following treatment.The FDA's recent request reignited scrutiny of the therapy's safety profile. Shares of Sarepta, down about 90% year-to-date, fell 5% on Monday to close at $13.32 on Nasdaq.- EndsWith inputs from Reuters
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
an hour ago
- First Post
WHO warns of global chikungunya comeback amid surging 2025 outbreaks
The latest surge began in early 2025, with severe outbreaks in the same Indian Ocean islands that had previously been affected, notably La Reunion, Mayotte, and Mauritius. read more A female mosquito is seen on the forearm of a health technician in a laboratory at the entomology department of the Ministry of Public Health in Guatemala City. File image/ Reuters The World Health Organization issued an urgent call to action on Tuesday to prevent a recurrence of the mosquito-borne chikungunya virus epidemic that swept the globe two decades ago, as fresh outbreaks related to the Indian Ocean region spread to Europe and other continents. Diana Rojas Alvarez, a medical official at the WHO, told reporters in Geneva that an estimated 5.6 billion people reside in regions of 119 nations where the virus can cause high fever, joint discomfort, and long-term impairment. STORY CONTINUES BELOW THIS AD 'We are seeing history repeating itself,' she said, drawing parallels to the 2004-2005 epidemic, which affected nearly half a million people, primarily in small island territories, before spreading around the world. The latest surge began in early 2025, with severe outbreaks in the same Indian Ocean islands that had previously been affected, notably La Reunion, Mayotte, and Mauritius. Rojas Alvarez estimates that one-third of La Reunion's population has already been affected. The virus is already moving to Madagascar, Somalia, and Kenya, and it has caused epidemic transmission in Southeast Asia, including India. The rising number of imported cases, as well as recent local transmission inside Europe, are particularly concerning. Rojas Alvarez reported that there have been approximately 800 imported chikungunya cases in continental France since May 1. Twelve local transmission episodes have been detected in several southern French regions, meaning individuals were infected by local mosquitoes without having travelled to endemic areas. A case was also detected last week in Italy. Chikungunya, for which there is no specific treatment and which is spread primarily by Aedes mosquito species, including the 'tiger mosquito' which also transmits dengue, and Zika, can cause rapid and large outbreaks. As the mosquitoes bite in the daytime, prevention is key, through the use of insect repellent and long-sleeved clothing. STORY CONTINUES BELOW THIS AD
Time of India
6 hours ago
- Time of India
Sarepta shares fall 7% after gene therapy maker pauses Elevidys shipments in US
Shares of Sarepta Therapeutics fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United States. The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily halt shipments of the gene therapy, but the company refused to do so and said it would continue making the treatment available to ambulatory patients. Explore courses from Top Institutes in Please select course: Select a Course Category Product Management Technology Degree Others Management Artificial Intelligence Public Policy MCA others PGDM healthcare Design Thinking Operations Management Finance Data Analytics Project Management MBA CXO Digital Marketing Leadership Data Science Data Science Skills you'll gain: Product Strategy & Competitive Advantage Tactics Product Development Processes & Market Orientations Product Analytics & Data-Driven Decision Making Agile Development, Design Thinking, & Product Leadership Duration: 40 Weeks IIM Kozhikode Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details Skills you'll gain: Product Strategy & Roadmapping User-Centric Product Design Agile Product Development Market Analysis & Product Launch Duration: 24 Weeks Indian School of Business Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details Skills you'll gain: Creating Effective Product Roadmap User Research & Translating it to Product Design Key Metrics via Product Analytics Hand-On Projects Using Cutting Edge Tools Duration: 12 Weeks Indian School of Business ISB Product Management Starts on May 14, 2024 Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trekking pants for mountain sports and adventure travel Trek Kit India Shop Now But Sarepta has now voluntarily and temporarily paused all shipments of the therapy, effective end of Tuesday. The company said the decision would allow it to respond to requests from the FDA and maintain a positive relationship with the agency. "Though Sarepta claims its pause in shipments was voluntary, we think the company moved preemptively - bracing for an inevitable FDA mandate to pull the drug," said H.C. Wainwright analyst Mitchell Kapoor. Shares of Sarepta fell 6.9% to $12.40 in early trading on Tuesday. Live Events "Sarepta's decision to comply was a capitulation after recognizing that the fight with the FDA was not winnable and that the agency would have strong-armed Sarepta into removing Elevidys with a formal demand," Kapoor added. Investor concerns regarding the use of the company's treatments have been heightened after the company on Friday disclosed that another patient who had received its experimental gene therapy died from acute liver failure , marking the third death this year. The company's shares have plummeted 89% so far this year. On Monday, Children's Hospital Los Angeles said it had paused usage of Elevidys in all patients with muscular dystrophy . The FDA's initial request had likely heightened the pressure on physicians to pause treatments, which could also have been a driving factor in Sarepta's decision, William Blair analyst Sami Corwin said.
The Hindu
7 hours ago
- The Hindu
Alzheimer's disease: Researchers find two cancer drugs reverse damaged gene behaviour in mice
A study that compared gene behaviour in Alzheimer's disease with that caused by 1,300 drugs approved for use in the US has found that a combination of two cancer drugs could slow the neurodegenerative disease in mice, indicating a promise in reversing symptoms in humans. Alzheimer's disease is an ageing-related disorder in which cognitive function steadily declines, affecting speech and memory, and eventually can interfere with everyday activities. Scientists at the University of California, San Francisco, and Gladstone Institutes in the US first saw how gene behaviour was affected in Alzheimer's disease in a single brain cell. The researchers then looked at 1,300 drugs approved by the US Food and Drug Administration (FDA) and which of them reversed the damage. The next stage of the study, published in the journal 'Cell', analysed electronic medical records of about 1.4 million patients and found that patients who took some of these drugs for treating conditions other than Alzheimer's disease were less likely to get the ageing-related neurological disorder. Testing the top two drug candidates -- 'letrozole' and 'irinotecan', both of which are cancer medications -- in a mouse model having Alzheimer's disease, the researchers found that brain degeneration was reduced and a restored ability to remember. Letrozole is usually prescribed for treating breast cancer, and irinotecan for colon and lung cancer. The combined effects of two drugs were found to reverse damaged gene behaviour in neurons and glia (a type of brain cells that surround and support neurons). Further, toxic clumps of proteins and brain degeneration -- hallmark features of Alzheimer's -- were found to be reduced and memory restored, the researchers said. The team added that out of 1,300 drugs, 86 reversed gene behaviour changes in one type of brain cell and 25 reversed them in other types. However, only 10 had been approved for use in humans by the FDA. "Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five," said lead author Yaqiao Li, a postdoctoral scholar at Gladstone Institutes. "Alzheimer's disease comes with complex changes to the brain which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly," said co-senior author Marina Sirota, professor of paediatrics and an interim director at the University of California. Co-senior author Yadong Huang, director of the center for translational advancement at Gladstone Institutes, said, "Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health." "This makes it very challenging for drug development -- which traditionally produces one drug for a single gene or protein that drives disease," Huang said. The electronic medical records analysed in the study came from the University of California's Health Data Warehouse, which includes anonymised health information on 1.4 million people over the age of 65.
